» Articles » PMID: 11714962

Vaccine-enhanced Respiratory Syncytial Virus Disease in Cotton Rats Following Immunization with Lot 100 or a Newly Prepared Reference Vaccine

Overview
Journal J Gen Virol
Specialty Microbiology
Date 2001 Nov 21
PMID 11714962
Citations 120
Authors
Affiliations
Soon will be listed here.
Abstract

A formalin-inactivated respiratory syncytial virus vaccine was used to immunize infants in the mid-1960s; when these children later were naturally infected by the virus they developed markedly accentuated disease, and two died. For the present work, a new batch of vaccine was prepared using the original formula. Administration of either the old or new vaccines resulted in enhanced lesions in immunized cotton rats subsequently challenged with live virus, although administration of the vaccine reduced virus replication by 90%. Animals primed with formalin-inactivated virus and challenged developed markedly accentuated lesions of the same type as in animals undergoing primary or secondary infection. In addition, the animals with the vaccine-enhanced disease developed alveolitis and interstitial pneumonitis, which appear to be specific markers for the vaccine enhancement. The newly prepared vaccine appears suitable as a reference standard for studying the mechanism of vaccine-enhanced disease caused by this virus. Additionally, we reviewed the lesions in the lungs of the two humans who died with the vaccine-enhanced disease in 1967, and found that they were similar to, but more severe than those seen in the cotton rats.

Citing Articles

A truncated pre-F protein mRNA vaccine elicits an enhanced immune response and protection against respiratory syncytial virus.

Lin M, Yin Y, Zhao X, Wang C, Zhu X, Zhan L Nat Commun. 2025; 16(1):1386.

PMID: 39910047 PMC: 11799228. DOI: 10.1038/s41467-025-56302-1.


An mRNA-Based Respiratory Syncytial Virus Vaccine Elicits Strong Neutralizing Antibody Responses and Protects Rodents Without Vaccine-Associated Enhanced Respiratory Disease.

Li J, Long H, Chen S, Zhang Z, Li S, Liu Q Vaccines (Basel). 2025; 13(1).

PMID: 39852831 PMC: 11768429. DOI: 10.3390/vaccines13010052.


The Development of Animal Models for Respiratory Syncytial Virus (RSV) Infection and Enhanced RSV Disease.

Zhang G, Zhao B, Liu J Viruses. 2024; 16(11).

PMID: 39599816 PMC: 11598872. DOI: 10.3390/v16111701.


Design of hepadnavirus core protein-based chimeric virus-like particles carrying epitopes from respiratory syncytial virus.

Shao S, Zhang X, Hou J, Yang S, Han Z, Wu H NPJ Vaccines. 2024; 9(1):62.

PMID: 38503757 PMC: 10951352. DOI: 10.1038/s41541-024-00855-7.


Ally, adversary, or arbitrator? The context-dependent role of eosinophils in vaccination for respiratory viruses and subsequent breakthrough infections.

Chang L, Schotsaert M J Leukoc Biol. 2024; 116(2):224-243.

PMID: 38289826 PMC: 11288382. DOI: 10.1093/jleuko/qiae010.